Evidence map›Paper›PMID 39604512›Full record

ArticleScientific reports2024

Photoacoustic polydopamine-indocyanine green (PDA-ICG) nanoprobe for detection of senescent cells.

Muhamad Hartono, Andrew G Baker, Thomas R Else, Alexander S Evtushenko, Sarah E Bohndiek, Daniel Muñoz-Espín, Ljiljana Fruk

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Early Radiation Therapy Response Assessment Using Multi-Scale Photoacoustic Imaging.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Muhamad Hartono *Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK.
Andrew G Baker *Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK.
Thomas R ElseCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
Alexander S EvtushenkoDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK.
Sarah E BohndiekCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
Daniel Muñoz-EspínEarly Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK.
Ljiljana FrukDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK. lf389@cam.ac.uk.

Funding

Cancer Research UK C9545/A29580Cancer Research UK (CRUK) Cambridge Centre Early Detection Programme RG86786CRUK Early Detection Primer Award EDDPMA-May23/100051CRUK Early Detection Project Award C62187/A26989CRUK Programme Foundation Award C62187/A29760Darley/Sands Downing College Fellowship G109261EPSRC EP/R003599/1EPSRC IRC grant EPSRC IRC, EP/S009000/1Medical Research Council MR/R000530/1Medical Research Council (MRC) New Investigator Research Grant (NIRG) MR/R000530/1
6 · The paper itself

Abstract

Cellular senescence is considered an important tumour suppression mechanism in response to damage and oncogenic stress in early lesions. However, when senescent cells are not immune-cleared and persist in the tumour microenvironment, they can drive a variety of tumour-promoting activities, including cancer initiation, progression, and metastasis. Additionally, there is compelling evidence demonstrating a direct connection between chemo(radio)therapy-induced senescence and the development of drug resistance and cancer recurrence. Therefore, detection of senescent cells in tissues holds great promise for predicting cancer occurrence earlier, assessing tumour progression, aiding patient stratification and prognosis, and informing about the efficacy of potential senotherapies. However, effective detection of senescent cells is limited by lack of biomarkers and readout strategies suitable for in vivo clinical imaging. To this end, a nanoprobe composed of biocompatible polydopamine (PDA) nanoparticle doped with FDA-approved indocyanine green (ICG) dye, namely PDA-ICG, was designed as a contrast agent for senescence detection using photoacoustic imaging (PAI). In an in vitro model of chemotherapy-induced senescence, PDA-ICG nanoprobe showed an elevated uptake in senescent cells relative to cancer cells. In addition to its improved photostability, 2.5-fold enhancement in photoacoustic signal relative to ICG was observed. Collectively, the results indicate that the PDA-ICG nanoprobe has the potential to be used as a contrast agent for senescence detection of chemotherapy-induced senescence using PAI.

Indexed as

Cellular SenescenceIndocyanine GreenIndolesNanoparticlesPhotoacoustic TechniquesPolymersCell Line, TumorHumansTumor MicroenvironmentIndocyanine GreenIndolespolydopaminePolymersCancerDetectionICGPhotoacousticPolydopamineSenescence

Identifiers

PMID39604512
PMCPMC11603024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.